Literature DB >> 30429198

FLI1 Exonic Circular RNAs as a Novel Oncogenic Driver to Promote Tumor Metastasis in Small Cell Lung Cancer.

Lingyu Li1, Wei Li1, Naifei Chen1,2, Haixin Zhao3, Guang Xu3, Yijing Zhao1,2, Xin Pan3, Xiaoying Zhang1, Lei Zhou1, Dehai Yu1, Ailing Li4, Ji-Fan Hu5,2, Jiuwei Cui5.   

Abstract

PURPOSE: The aberrantly upregulated Friend leukemia virus integration 1 (FLI1) is closely correlated with the malignant phenotype of small cell lung cancer (SCLC). It is interesting to note that the CRISPR gene knockout by Cas9 gRNAs that target the FLI1 coding region and the posttranscriptional knockdown by shRNAs that target the 3' region of FLI1 mRNA yielded distinct antimetastasis effects in SCLC cells. This study attempts to examine if FLI1 exonic circular RNAs (FECR) function as a new malignant driver that determines the metastatic phenotype in SCLC. EXPERIMENTAL
DESIGN: The clinical relevance of FECRs was examined in 56 primary SCLC tissues and 50 non-small cell lung cancer (NSCLC) tissues. The prognostic value of FECRs was examined by measuring serum exosomal FECRs in a longitudinal cohort of patients with SCLC. The oncogenic activity of FECRs was investigated in both SCLC cell lines and animal xenograft studies. Finally, we explored the molecular mechanisms underlying these noncoding RNAs as a malignant driver.
RESULTS: Therapeutic comparison of CRISPR Cas9 knockout and shRNA knockdown of FLI1 identified FECRs as a new noncanonical malignant driver in SCLC. Using RNA FISH and quantitative PCR, we found that FECR1 (exons 4-2-3) and FECR2 (exons 5-2-3-4) were aberrantly upregulated in SCLC tissues (P < 0.0001), and was positively associated with lymph node metastasis (P < 0.01). Notably, serum exosomal FECR1 was associated with poor survival (P = 0.038) and clinical response to chemotherapy. Silencing of FECRs significantly inhibited the migration in two highly aggressive SCLC cell lines and reduced tumor metastasis in vivo. Mechanistically, we uncovered that FECRs sequestered and subsequently inactivated tumor suppressor miR584-3p, leading to the activation of the Rho Associated Coiled-Coil Containing Protein Kinase 1 gene (ROCK1).
CONCLUSIONS: This study identifies FLI1 exonic circular RNAs as a new oncogenic driver that promotes tumor metastasis through the miR584-ROCK1 pathway. Importantly, serum exosomal FECR1 may serve as a promising biomarker to track disease progression of SCLC. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30429198     DOI: 10.1158/1078-0432.CCR-18-1447

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

1.  Aberrant shuttling of long noncoding RNAs during the mitochondria-nuclear crosstalk in hepatocellular carcinoma cells.

Authors:  Yijing Zhao; Shanshan Liu; Lei Zhou; Xueli Li; Ying Meng; Yan Li; Lingyu Li; Benzheng Jiao; Ling Bai; Yu Yu; Songling Zhang; Wei Li; Andrew R Hoffman; Ji-Fan Hu; Jiuwei Cui
Journal:  Am J Cancer Res       Date:  2019-05-01       Impact factor: 6.166

Review 2.  Extracellular vesicles in pharmacology: Novel approaches in diagnostics and therapy.

Authors:  Zainuddin Quadri; Ahmed Elsherbini; Erhard Bieberich
Journal:  Pharmacol Res       Date:  2021-12-02       Impact factor: 7.658

Review 3.  The emerging roles of circRNAs in cancer and oncology.

Authors:  Lasse S Kristensen; Theresa Jakobsen; Henrik Hager; Jørgen Kjems
Journal:  Nat Rev Clin Oncol       Date:  2021-12-15       Impact factor: 66.675

Review 4.  Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star.

Authors:  Qun Chen; Jiajia Li; Peng Shen; Hao Yuan; Jie Yin; Wanli Ge; Wujun Wang; Guangbin Chen; Taoyue Yang; Bin Xiao; Yi Miao; Zipeng Lu; Pengfei Wu; Kuirong Jiang
Journal:  Cell Biosci       Date:  2022-06-21       Impact factor: 9.584

5.  Profiling the epigenetic interplay of lncRNA RUNXOR and oncogenic RUNX1 in breast cancer cells by gene in situ cis-activation.

Authors:  Yuanyuan Nie; Lei Zhou; Hong Wang; Naifei Chen; Lin Jia; Cong Wang; Yichen Wang; Jingcheng Chen; Xue Wen; Chao Niu; Hui Li; Rui Guo; Songling Zhang; Jiuwei Cui; Andrew R Hoffman; Ji-Fan Hu; Wei Li
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

Review 6.  Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review.

Authors:  Jishnu Nair; Abhishek Nair; Soundaram Veerappan; Dwaipayan Sen
Journal:  Cancer Gene Ther       Date:  2019-06-20       Impact factor: 5.987

Review 7.  Insights Into circRNAs: Functional Roles in Lung Cancer Management and the Potential Mechanisms.

Authors:  Bing Feng; Hao Zhou; Ting Wang; Xinrong Lin; Yongting Lai; Xiaoyuan Chu; Rui Wang
Journal:  Front Cell Dev Biol       Date:  2021-02-09

Review 8.  The role of exosomes in lung cancer metastasis and clinical applications: an updated review.

Authors:  Lei Yin; Xiaotian Liu; Xuejun Shao; Tao Feng; Jun Xu; Qi Wang; Shenghao Hua
Journal:  J Transl Med       Date:  2021-07-19       Impact factor: 5.531

9.  Chronic Obstructive Pulmonary Disease Is Associated with Epigenome-Wide Differential Methylation in BAL Lung Cells.

Authors:  Jonas Eriksson Ström; Simon Kebede Merid; Jamshid Pourazar; Anders Blomberg; Anne Lindberg; Mikael V Ringh; Michael Hagemann-Jensen; Tomas J Ekström; Annelie F Behndig; Erik Melén
Journal:  Am J Respir Cell Mol Biol       Date:  2022-06       Impact factor: 7.748

Review 10.  Emerging Function and Clinical Significance of Exosomal circRNAs in Cancer.

Authors:  Man Wang; Fei Yu; Peifeng Li; Kun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-12       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.